{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:17:57Z","timestamp":1791530277954,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,11,30]],"date-time":"2019-11-30T00:00:00Z","timestamp":1575072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"US Food and Drug Administration","award":["HHSF223201510104C"],"award-info":[{"award-number":["HHSF223201510104C"]}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"crossref","award":["197785619\/SFB 1021"],"award-info":[{"award-number":["197785619\/SFB 1021"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_12014\/1"],"award-info":[{"award-number":["MC_UU_12014\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["102789\/Z\/13\/A"],"award-info":[{"award-number":["102789\/Z\/13\/A"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck\/WHO"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In October 2015, 65 people came into direct contact with a healthcare worker presenting with a late reactivation of Ebola virus disease (EVD) in the United Kingdom. Vaccination was offered to 45 individuals with an initial assessment of high exposure risk.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Approval for rapid expanded access to the recombinant vesicular stomatitis virus\u2013Zaire Ebola virus (rVSV-ZEBOV) vaccine as an unlicensed emergency medicine was obtained from the relevant authorities. An observational follow-up study was carried out for 1 year following vaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-six of 45 individuals elected to receive vaccination between 10 and 11 October 2015 following written informed consent. By day 14, 39% had seroconverted, increasing to 87% by day 28 and 100% by 3 months, although these responses were not always sustained. Neutralizing antibody responses were detectable in 36% by day 14 and 73% at 12 months. Common side effects included fatigue, myalgia, headache, arthralgia, and fever. These were positively associated with glycoprotein-specific T-cell but not immunoglobulin (Ig) M or IgG antibody responses. No severe vaccine-related adverse events were reported. No one exposed to the virus became infected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This paper reports the use of the rVSV-ZEBOV vaccine given as an emergency intervention to individuals exposed to a patient presenting with a late reactivation of EVD. The vaccine was relatively well tolerated, but a high percentage developed a fever \u226537.5\u00b0C, necessitating urgent screening for Ebola virus, and a small number developed persistent arthralgia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz1165","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T20:10:55Z","timestamp":1574971855000},"page":"2872-2879","source":"Crossref","is-referenced-by-count":25,"title":["Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report"],"prefix":"10.1093","volume":"71","author":[{"given":"Chris","family":"Davis","sequence":"first","affiliation":[{"name":"Medical Research Council\u2013University of Glasgow Centre for Virus Research, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Tipton","sequence":"additional","affiliation":[{"name":"Porton Down, National Infection Service, Public Health England, Salisbury, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleman","family":"Sabir","sequence":"additional","affiliation":[{"name":"Medical Research Council\u2013University of Glasgow Centre for Virus Research, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Aitken","sequence":"additional","affiliation":[{"name":"West of Scotland Specialist Virology Centre, Glasgow Royal Infirmary, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Bennett","sequence":"additional","affiliation":[{"name":"West of Scotland Specialist Virology Centre, Glasgow Royal Infirmary, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-9350","authenticated-orcid":false,"given":"Stephan","family":"Becker","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Katharina","family":"Fehling","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Gunson","sequence":"additional","affiliation":[{"name":"West of Scotland Specialist Virology Centre, Glasgow Royal Infirmary, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yper","family":"Hall","sequence":"additional","affiliation":[{"name":"Porton Down, National Infection Service, Public Health England, Salisbury, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Jackson","sequence":"additional","affiliation":[{"name":"West of Scotland Specialist Virology Centre, Glasgow Royal Infirmary, Glasgow, United Kingdom"},{"name":"Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolfur","family":"Johanssen","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Paule","family":"Kieny","sequence":"additional","affiliation":[{"name":"World Health Organization, Geneva, Switzerland"},{"name":"Inserm, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Mcmenamin","sequence":"additional","affiliation":[{"name":"Health Protection Scotland, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Spence","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Strecker","sequence":"additional","affiliation":[{"name":"Institute of Virology, Philipps University Marburg, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catie","family":"Sykes","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Templeton","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Thorburn","sequence":"additional","affiliation":[{"name":"West of Scotland Specialist Virology Centre, Glasgow Royal Infirmary, Glasgow, United Kingdom"},{"name":"Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Henao Restrepo","sequence":"additional","affiliation":[{"name":"World Health Organization, Geneva, Switzerland"},{"name":"Inserm, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"White","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Zambon","sequence":"additional","affiliation":[{"name":"Public Health England Colindale, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles W","family":"Carroll","sequence":"additional","affiliation":[{"name":"Porton Down, National Infection Service, Public Health England, Salisbury, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1482-0889","authenticated-orcid":false,"given":"Emma C","family":"Thomson","sequence":"additional","affiliation":[{"name":"Medical Research Council\u2013University of Glasgow Centre for Virus Research, Glasgow, United Kingdom"},{"name":"Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,30]]},"reference":[{"key":"2021010207403831800_CIT0001"},{"key":"2021010207403831800_CIT0002","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(16)30386-5","article-title":"Late Ebola virus relapse causing meningoencephalitis: a case report","volume":"388","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"2021010207403831800_CIT0003","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"2021010207403831800_CIT0004","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"Ebola vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"2021010207403831800_CIT0005","doi-asserted-by":"crossref","first-page":"S785","DOI":"10.1093\/infdis\/jir298","article-title":"Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany","volume":"204","author":"G\u00fcnther","year":"2011","journal-title":"J Infect Dis"},{"key":"2021010207403831800_CIT0006","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(17)30677-1","article-title":"Ebola virus disease: an update on post-exposure prophylaxis","volume":"18","author":"Fischer","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021010207403831800_CIT0007","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1473-3099(15)00228-5","article-title":"Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers","volume":"15","author":"Jacobs","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021010207403831800_CIT0008","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 placebo-controlled trial of two vaccines to prevent ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N Engl J Med"},{"key":"2021010207403831800_CIT0009","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/JCM.02287-15","article-title":"Evaluation of the Biofire FilmArray BioThreat-E Test (v2.5) for rapid identification of ebola virus disease in heat-treated blood samples obtained in Sierra Leone and the United Kingdom","volume":"54","author":"Weller","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2021010207403831800_CIT0010","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N Engl J Med"},{"key":"2021010207403831800_CIT0011","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00430-015-0438-6","article-title":"Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus","volume":"205","author":"Kr\u00e4hling","year":"2016","journal-title":"Med Microbiol Immunol"},{"key":"2021010207403831800_CIT0012","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"2021010207403831800_CIT0013","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N Engl J Med"},{"key":"2021010207403831800_CIT0014","doi-asserted-by":"crossref","first-page":"20920","DOI":"10.2807\/1560-7917.ES2014.19.40.20920","article-title":"Transmission dynamics and control of Ebola virus disease outbreak in Nigeria, July to September 2014","volume":"19","author":"Fasina","year":"2014","journal-title":"Euro Surveill"},{"key":"2021010207403831800_CIT0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"2021010207403831800_CIT0016","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"key":"2021010207403831800_CIT0017","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1371\/journal.ppat.0030002","article-title":"Effective post-exposure treatment of Ebola infection","volume":"3","author":"Feldmann","year":"2007","journal-title":"PLoS Pathog"},{"key":"2021010207403831800_CIT0018","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021010207403831800_CIT0019","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/cid\/ciw256","article-title":"Use of postexposure prophylaxis after occupational exposure to Zaire ebolavirus","volume":"63","author":"Wong","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021010207403831800_CIT0020","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/cid\/civ131","article-title":"Risk of misinterpretation of Ebola virus PCR results after rVSV ZEBOV-GP vaccination","volume":"60","author":"Cnops","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021010207403831800_CIT0021","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021010207403831800_CIT0022","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.celrep.2017.08.023","article-title":"Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the ebola vaccine rVSV-ZEBOV","volume":"20","author":"Rechtien","year":"2017","journal-title":"Cell Rep"},{"key":"2021010207403831800_CIT0023","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization","volume":"19","author":"Dahlke","year":"2017","journal-title":"EBioMedicine"},{"key":"2021010207403831800_CIT0024","doi-asserted-by":"crossref","first-page":"S443","DOI":"10.1093\/infdis\/jiv316","article-title":"Vaccination with a highly attenuated recombinant vesicular stomatitis virus vector protects against challenge with a lethal dose of ebola virus","volume":"212","author":"Matassov","year":"2015","journal-title":"J Infect Dis"},{"key":"2021010207403831800_CIT0025","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/infdis\/jiw218","article-title":"Efficacy of vesicular stomatitis virus-ebola virus postexposure treatment in rhesus macaques infected with Ebola virus Makona","volume":"214","author":"Marzi","year":"2016","journal-title":"J Infect Dis"},{"key":"2021010207403831800_CIT0026","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1016\/j.vaccine.2017.05.097","article-title":"Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic","volume":"35","author":"Coller","year":"2017","journal-title":"Vaccine"},{"key":"2021010207403831800_CIT0027","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/infdis\/jiy698","article-title":"PREVAIL I cluster vaccination study with rVSVG-ZEBOV-GP as part of a public health response in Liberia","volume":"219","author":"Bolay","year":"2019","journal-title":"J Infect Dis"},{"key":"2021010207403831800_CIT0028","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(18)30165-8","article-title":"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study","volume":"18","author":"Huttner","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021010207403831800_CIT0029","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jama.2015.1995","article-title":"Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick","volume":"313","author":"Lai","year":"2015","journal-title":"JAMA"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz1165\/31862507\/ciz1165.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/11\/2872\/35349597\/ciz1165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/11\/2872\/35349597\/ciz1165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T12:41:04Z","timestamp":1609591264000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/11\/2872\/5648103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,30]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,30]]},"published-print":{"date-parts":[[2020,12,31]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz1165","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2019,11,30]]}}}